Safety and Pharmacokinetics of Nirsevimab in Japanese Infants: Primary Analysis of the Open-Label JUBILUS Trial
{{output}}
In Japanese infants aged ≤12 months at risk for severe respiratory syncytial virus-associated lower respiratory tract infections who received two doses of nirsevimab 5-6 months apart, no safety concerns or anti-drug antibodies occurred. Nirsevimab serum conce... ...
